• Explore /
  • Poster
  • / PLUME: A single-arm phase II trial evaluating the combination of pembrolizumab and lenvatinib in metastatic uveal melanoma (mUM) patients (pts) previously treated or not with tebentafusp.

PLUME: A single-arm phase II trial evaluating the combination of pembrolizumab and lenvatinib in metastatic uveal melanoma (mUM) patients (pts) previously treated or not with tebentafusp.

Abstract Poster

Authors

null

Manuel Rodrigues

Medical Oncology Department, Institut Curie, Paris, France

Manuel Rodrigues , Mathilde Saint-Ghislain , Toulsie Ramtohul , Leanne de Koning , Clémentine Bouchez , Elsa Lafite , Zahra Castel Ajgal , Gregoire Marret , Raphaël Sanchez , Pascale Mariani , Sandra Nespoulous , Véronique Gillon , Vincent Servois , Sophie Piperno-Neumann

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Other Melanoma/Skin Cancers

Clinical Trial Registration Number

NCT05282901

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS9613)

DOI

10.1200/JCO.2023.41.16_suppl.TPS9613

Abstract #

TPS9613

Poster Bd #

365b

Abstract Disclosures

Similar Posters

First Author: Maliheh Mohamadpour

First Author: Shipra Gandhi

First Author: Elshad Hasanov

Poster

2024 ASCO Gastrointestinal Cancers Symposium

Phase 2 study of pembrolizumab plus lenvatinib and belzutifan in patients with metastatic esophageal squamous cell carcinoma.

Phase 2 study of pembrolizumab plus lenvatinib and belzutifan in patients with metastatic esophageal squamous cell carcinoma.

First Author: Carlos Rojas